Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time?

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Targeted molecular therapies and immuno-oncology are crucial for lung cancer management.
• High-throughput biomarker analysis and validation are essential due to limited response rates (20%-30%) with evolving treatment options.
• Tumor molecular profiling and immune contexture can predict treatment response or resistance.

Purpose of the Study:

• To review the technological status and clinical applications of multiplexed immunohistochemistry (IHC) in lung cancer.
• To explore how multiplexed IHC can optimize clinical management and treatment strategies.
• To highlight the utility of multiplexed IHC in identifying predictive biomarkers and understanding immune evasion.

Main Methods:

• Multiplexed immunohistochemistry (IHC) enables simultaneous identification of specific proteins and molecular abnormalities.
• This technique assesses the spatial distribution and activation state of immune cells.
• It also detects immunoactive molecular expression within the tumor microenvironment.

Main Results:

• Multiplexed IHC is effective for investigating immune evasion mechanisms.
• It facilitates the discovery of potential biomarkers for assessing treatment mechanisms of action.
• The method aids in predicting patient response to specific therapies.

Conclusions:

• Multiplexed IHC is a proficient approach for comprehensive molecular and immune profiling in lung cancer.
• It offers significant advantages for biomarker discovery and validation.
• The application of multiplexed IHC can lead to optimized clinical management and improved patient outcomes in lung cancer treatment.